Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 76.7x - 84.8x | 80.7x |
| Selected Fwd P/E Multiple | 22.5x - 24.9x | 23.7x |
| Fair Value | €27.24 - €30.11 | €28.68 |
| Upside | -10.9% - -1.5% | -6.2% |
| Benchmarks | - | Full Ticker |
| Exelixis, Inc. | - | NasdaqGS:EXEL |
| Vanda Pharmaceuticals Inc. | - | NasdaqGM:VNDA |
| Shattuck Labs, Inc. | - | NasdaqGS:STTK |
| Pyxis Oncology, Inc. | - | NasdaqGS:PYXS |
| Zai Lab Limited | - | NasdaqGM:ZLAB |
| TG Therapeutics, Inc. | - | DB:NKB2 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| EXEL | VNDA | STTK | PYXS | ZLAB | NKB2 | |||
| NasdaqGS:EXEL | NasdaqGM:VNDA | NasdaqGS:STTK | NasdaqGS:PYXS | NasdaqGM:ZLAB | DB:NKB2 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 10.2% | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | 31.2% | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 72.1% | -512.6% | 17.0% | -64.8% | 25.6% | -5.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 15.2% | 1.1% | -3613.2% | -389.7% | -322.8% | -27846.4% | ||
| Prior Fiscal Year | 11.4% | 1.3% | -5268.4% | NA | -125.5% | 5.4% | ||
| Latest Fiscal Year | 24.0% | -9.5% | -1318.1% | -478.9% | -64.4% | 7.1% | ||
| Latest Twelve Months | 28.0% | -32.9% | -1533.0% | NA | -60.3% | 10.1% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 11.3x | 0.7x | 0.3x | 0.2x | -13.7x | 84.9x | ||
| Price / LTM Sales | 4.5x | 1.2x | 7.6x | NA | 9.7x | 13.2x | ||
| LTM P/E Ratio | 16.7x | -3.7x | -0.5x | -0.7x | -16.2x | 130.4x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -16.2x | -0.7x | 16.7x | |||||
| Historical LTM P/E Ratio | -300.7x | -29.0x | -6.6x | |||||
| Selected P/E Multiple | 76.7x | 80.7x | 84.8x | |||||
| (x) LTM Net Income | 39 | 39 | 39 | |||||
| (=) Equity Value | 3,003 | 3,161 | 3,319 | |||||
| (/) Shares Outstanding | 145.8 | 145.8 | 145.8 | |||||
| Implied Value Range | 20.59 | 21.68 | 22.76 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 17.78 | 18.72 | 19.66 | 30.57 | ||||
| Upside / (Downside) | -41.8% | -38.8% | -35.7% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | EXEL | VNDA | STTK | PYXS | ZLAB | NKB2 | |
| Value of Common Equity | 10,030 | 248 | 35 | 68 | 4,072 | 5,162 | |
| (/) Shares Outstanding | 269.2 | 59.1 | 47.9 | 61.9 | 110.6 | 145.8 | |
| Implied Stock Price | 37.26 | 4.19 | 0.73 | 1.10 | 36.82 | 35.40 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |
| Implied Stock Price (Trading Cur) | 37.26 | 4.19 | 0.73 | 1.10 | 36.82 | 30.57 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |